High-dose hepatitis B immunoglobulin therapy in hepatocellular carcinoma with hepatitis B virus-DNA/hepatitis B e antigen-positive patients after living donor liver transplantation

Table 1 Baseline characteristics of all patients

Characteristic	Met the Milan criteria (n = 109)			Did not meet the Milan criteria (n = 59)
	Low-dose HBIG	High-dose HBIG	P value	Low-dose HBIG	High-dose HBIG	P value
	(n = 62)	(n = 47)		(n = 33)	(n = 26)
Age (yr)	53.8 ± 6.4	53.6 ± 7.6	0.854	54.1 ± 7.4	53.0 ± 8.7	0.608
Sex (male/female)	49/13	35/12	0.575	30/3	21/5	0.284
Child-Pugh score	7 (5-13)	5 (5-12)	0.002	7 (5-13)	6 (5-13)	0.226
AFP (ng/mL)	18.8 (2.0-8891.8)	13.3 (1.8-3811.2)	0.407	30.7 (3.5-31142.9)	235.3 (2.9-57348.8)	0.049
Number of tumors	1 (1-3)	1 (1-3)	0.857	1 (1-8)	1 (1-5)	0.743
Largest tumor size (cm)	2.2 (0.6-4.5)	2.2 (0.8-4.0)	0.504	5.4 (0.9-13.0)	4.9 (1.1-25.0)	0.976
Edmond-Steiner grade (I,II/III,IV)	26/36	21/26	0.774	8/25	2/24	0.161
Major vessel invasion (absent/present)	62/0	47/0	N/A	26/7	17/9	0.250
Microvascular invasion (absent/present)	42/17[3]	30/17	0.420	11/22	6/20	0.388
Bile duct invasion (absent/present)	61/1	42/2	0.577	31/2	23/3	0.646
Satellite nodule (absent/present)	46/15[1]	37/10	0.686	14/19	11/15	0.993

Values are presented as number/number, mean ± SD or median (range). Numbers in parentheses are missing value. AFP: Alpha-fetoprotein; N/A: Not applicable.